Shiying Yu

5.5k total citations · 1 hit paper
141 papers, 3.7k citations indexed

About

Shiying Yu is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shiying Yu has authored 141 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 46 papers in Molecular Biology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shiying Yu's work include Lung Cancer Treatments and Mutations (18 papers), Cancer survivorship and care (16 papers) and Nutrition and Health in Aging (12 papers). Shiying Yu is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Cancer survivorship and care (16 papers) and Nutrition and Health in Aging (12 papers). Shiying Yu collaborates with scholars based in China, United States and Australia. Shiying Yu's co-authors include Xun Yuan, Qian Chu, Kongming Wu, Hua Wu, Hanxiao Xu, Lei Sun, Na Han, Huihua Xiong, Sudip Thapa and Gen Sheng Wu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Shiying Yu

137 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Notch signaling: An emerging therapeutic target for cancer treatment

2015 325 citations Xun Yuan, Hua Wu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shiying Yu China	31	1.5k	1.3k	926	870	496	141	3.7k
Kurt Possinger Germany	35	1.5k 1.0×	2.2k 1.7×	788 0.9×	579 0.7×	278 0.6×	101	4.4k
Jaime Feliú Spain	35	1.2k 0.8×	2.5k 1.9×	1.1k 1.2×	790 0.9×	198 0.4×	245	4.4k
Virginia Kaklamani United States	42	1.6k 1.1×	2.1k 1.6×	943 1.0×	958 1.1×	636 1.3×	176	5.2k
Jyh‐Cherng Yu Taiwan	38	1.8k 1.2×	1.0k 0.8×	435 0.5×	811 0.9×	187 0.4×	147	4.0k
Shigeru Kanda Japan	45	2.8k 1.9×	962 0.7×	514 0.6×	1.0k 1.2×	430 0.9×	133	5.4k
Maosheng Huang United States	35	1.6k 1.1×	532 0.4×	637 0.7×	728 0.8×	269 0.5×	98	3.1k
Matteo Puntoni Italy	33	1.7k 1.1×	1.8k 1.4×	658 0.7×	1.2k 1.4×	230 0.5×	139	4.8k
Bernard V. North United Kingdom	24	1.1k 0.8×	753 0.6×	515 0.6×	646 0.7×	188 0.4×	60	3.2k
Qiwen Ben China	27	1.2k 0.8×	1.7k 1.3×	451 0.5×	619 0.7×	199 0.4×	47	3.1k
Olorunseun O. Ogunwobi United States	29	1.2k 0.8×	686 0.5×	463 0.5×	1.1k 1.3×	155 0.3×	86	2.8k

Countries citing papers authored by Shiying Yu

Since Specialization

Citations

This map shows the geographic impact of Shiying Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiying Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiying Yu more than expected).

Fields of papers citing papers by Shiying Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiying Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiying Yu. The network helps show where Shiying Yu may publish in the future.

Co-authorship network of co-authors of Shiying Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Shiying Yu. A scholar is included among the top collaborators of Shiying Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiying Yu. Shiying Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Lu, et al.. (2023). Ursolic Acid Alleviates Cancer Cachexia and Prevents Muscle Wasting via Activating SIRT1. Cancers. 15(8). 2378–2378. 16 indexed citations

Yu, Shiying, et al.. (2023). Advances in pharmacotherapies in cancer-related cachexia*. Oncology and Translational Medicine. 9(1). 15–21. 1 indexed citations

Zhou, Qing, Chong‐Rui Xu, Ying Cheng, et al.. (2021). Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 39(9). 1279–1291.e3. 144 indexed citations

Li, Lu, et al.. (2021). Pharmacological Inhibition of HMGB1 Prevents Muscle Wasting. Frontiers in Pharmacology. 12. 731386–731386. 21 indexed citations

Cheng, Yi, Yujie Zhang, Jie Rao, et al.. (2020). Mental health status of cancer caregivers, assessment tools, and psychological interventions*. Oncology and Translational Medicine. 6(4). 170–178. 1 indexed citations

Cheng, Yi, Yujie Zhang, Jie Rao, et al.. (2020). Assessing anxiety, depression, and stress among inpatients with cancer*. Oncology and Translational Medicine. 6(3). 126–130. 1 indexed citations

Ma, Fei, Quchang Ouyang, Wěi Li, et al.. (2019). Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. Journal of Clinical Oncology. 37(29). 2610–2619. 247 indexed citations

Zou, Yanmei, Shuo Yao, Xiuqiong Chen, et al.. (2018). LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells. European Journal of Cell Biology. 97(5). 369–378. 95 indexed citations

Kumar, Manish, Liangpeng Yang, David Molkentine, et al.. (2017). BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer. Clinical Cancer Research. 24(3). 600–607. 20 indexed citations

10.

Zhou, Ting, Kaixiang Yang, Sudip Thapa, et al.. (2016). Validation of the Chinese version of functional assessment of anorexia-cachexia therapy (FAACT) scale for measuring quality of life in cancer patients with cachexia. Supportive Care in Cancer. 25(4). 1183–1189. 11 indexed citations

11.

Yuan, Xun, Hua Wu, Hanxiao Xu, et al.. (2015). Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Scientific Reports. 5(1). 10338–10338. 102 indexed citations

12.

Keefe, Dorothy, Alexandre Chan, Hoon-Kyo Kim, et al.. (2014). Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. Supportive Care in Cancer. 23(1). 253–261. 7 indexed citations

13.

Wu, Yi‐Long, Yan Sun, Caicun Zhou, et al.. (2013). Survival without common toxicity criteria grade 3/4 toxicity following second-line treatment with pemetrexed for nonsquamous non-small cell lung cancer in Chinese patients. Chinese Medical Journal. 126(24). 4624–4628. 4 indexed citations

14.

Li, Longyun, Wei Zhong, Meilin Liao, et al.. (2012). [A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].. SHILAP Revista de lepidopterología. 15(6). 332–9. 5 indexed citations

15.

Zhao, Yin, et al.. (2010). Activated PI3K/Akt/COX-2 Pathway Induces Resistance to Radiation in Human Cervical Cancer HeLa Cells. Cancer Biotherapy and Radiopharmaceuticals. 25(3). 317–323. 66 indexed citations

16.

Huang, Jee‐Fu, Wan‐Long Chuang, Ming‐Lung Yu, et al.. (2009). Hepatitis C Virus Infection And Metabolic Syndrome—A Community‐Based Study in an Endemic Area of Taiwan. The Kaohsiung Journal of Medical Sciences. 25(6). 299–305. 36 indexed citations

17.

Liao, Meilin, Yunzhong Zhu, Longyun Li, et al.. (2008). Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial coducted in Chinese patients with nonsmall cell lung cancer. Chinese Medical Journal. 121(10). 892–897. 5 indexed citations

18.

Yu, Shiying, et al.. (2008). Correlation between the expression of aquaporin 1 and hypoxia-inducible factor 1 in breast cancer tissues. Journal of Huazhong University of Science and Technology [Medical Sciences]. 28(3). 346–348. 23 indexed citations

19.

Yu, Shiying, et al.. (2007). Changes of survivin mRNA and protein expression during paclitaxel treatment in breast cancer cells. Journal of Huazhong University of Science and Technology [Medical Sciences]. 27(1). 65–67. 10 indexed citations

20.

Xia, Shu, Shiying Yu, & Xianglin Yuan. (2005). Expression of Hypoxia Inducible Factor 1α and Its Significance in Non-small Cell Lung Cancer. The Chinese-German Journal of Clinical Oncology. 4(5). 284–286.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact